Urologic Oncology Branch, National Cancer Institute, Hematology Branch, National Heart Lung and Blood Institute, National Institutes for Health, Bethesda, MD, U.S.A.
Cytotechnology. 2003 Mar;41(2-3):197-206. doi: 10.1023/A:1024839225920.
Over the past few decades, great strides have been made to advance the field of allogeneic hematopoietic stem cell transplantation. The donor immune mediated graft-vs-tumor effect that follows the procedure is now widely accepted as the most effective form cancer immunotherapy available for patients with a variety of advanced hematological malignancies. Recognition that a transplanted immune system could cure patients with treatment refractory leukemia led to the development of ;low-intensity' conditioning regimens, which have improved the safety of the procedure and broadened the application of allogeneic immunotherapy to a growing list of neoplastic diseases. Here we discuss the investigational use of allogeneic transplantation as immunotherapy for patients with metastatic, treatment-refractory solid tumors.
在过去的几十年中，异体造血干细胞移植领域取得了重大进展。现在，人们广泛接受该程序后供体免疫介导的移植物抗肿瘤效应是治疗各种晚期血液恶性肿瘤患者最有效的癌症免疫疗法之一。认识到移植的免疫系统可以治愈治疗抵抗性白血病患者，导致了“低强度”预处理方案的发展，这提高了该程序的安全性，并将同种异体免疫治疗的应用扩展到越来越多的肿瘤疾病。在这里，我们讨论异体移植作为转移性、治疗抵抗性实体瘤患者免疫疗法的研究性应用。
